BCBruno Claustrat

Bruno Claustrat

*This is an algorithmically generated author record based on publicly available information.

Bruno Claustrat has a total of 59 co-authors. Here are the top co-authors by number of shared publications:

  • Jocelyne Brun

    Hormone Laboratory, Nuclear Medicine Centre; Hospices Civils de Lyon, France

    4 shared publications
  • C. Harthé

    Hormone Laboratory, Centre of Nuclear Medicine, Department of Chronobiology, Stem Cell and Brain Research Institute, Groupement Hospitalier Est, 59, boulevard Pinel, 69677 Bron, France

    2 shared publications
  • Françoise Borson-Chazot

    Endocrinology Federation, hôpital Louis-Pradel, hospices civils de Lyon, université Lyon 1, 28, avenue Doyen-Lépine, 69500 Bron, France

    2 shared publications
  • J. Leston

    Neurosurgical Unit A, P.-Wertheimer Hospital, Bron, France; Inserm, U846, Department of Chronobiology, Stem Cell and Brain Research Institute, Bron, France

    2 shared publications
  • Adyla Yacoubi

    UEC CIC 1426, Robert Debré Hospital, 75019 Paris, France

    1 shared publication
  • Alain Nicolas

    GénoPsy, Reference Center for Diagnosis and Management of Genetic Psychiatric Disorders, Centre Hospitalier le Vinatier and EDR-Psy Q19 Team (Centre National de la Recherche Scientifique & Lyon 1 Claude Bernard University), 69678 Bron, France

    1 shared publication

Latest Publications

  • Open Access

    Melatonin Levels in Preterm and Term Infants and Their Mothers

    by Valérie Biran, Fabrice Decobert, Nathalie Bednarek, Priscilla Boizeau, Jean-François Benoist, Bruno Claustrat, Jérôme Barré, Marina Colella, Alice Frérot, Roselyne Garnotel, et al.

    The prevention of perinatal brain damage following preterm birth remains a public health priority. Melatonin has been shown to be a promising neuroprotectant in neonatal preclinical models of brain damage, but few studies have investigated melatonin secretion in newborns. We hypothesized that melatonin circulating levels would be lower in preterm compared to term infants. We conducted a prospective, longitudinal, multicenter study to assess melatonin, and 6-sulfatoxy-melatonin (aMT6s) concentrations, measured by radioimmunoassay. Among 209 neonates recruited, 110 were born before 34 gestational weeks (GW) and 99 born after 34 GW. Plasma melatonin concentrations, measured at birth and on Day 3 were below detectable levels (≤7 pg/mL) in 78% and 81%, respectively, of infants born before 34 GW compared to 57% and 34%, respectively, of infants born after 34 GW. The distribution of plasma melatonin concentrations was found to be correlated with gestational age at both time-points (p < 0.001). Median urine aMT6s concentrations were significantly lower in infants born before 34 GW, both on Day 1 (230 ng/L vs. 533 ng/L, p < 0.0001) and on Day 3 (197 ng/L vs. 359 ng/L, p < 0.0001). In conclusion, melatonin secretion appears very low in preterm infants, providing the rationale for testing supplemental melatonin as a neuroprotectant in clinical trials.


  • Top Cited Papers

    Melatonin: Physiological effects in humans

    by B. Claustrat, J. Leston


  • Is pineal melatonin released in the third ventricle in humans? A study in movement disorders

    by J. Leston, C. Harthé, C. Mottolese, P. Mertens, M. Sindou, B. Claustrat


  • Open Access

    A dietary supplement to improve the quality of sleep: a randomized placebo controlled trial

    by Catherine Cornu, Laurent Remontet, Florence Noel-Baron, Alain Nicolas, Nathalie Feugier-Favier, Pascal Roy, Bruno Claustrat, Mitra Saadatian-Elahi, Behrouz Kassaï

    To evaluate the effect of a dietary supplement containing polyunsaturated fatty acids, in association with Humulus lupulus extract, on the quality of sleep using the Leeds sleep evaluation questionnaire (LSEQ) in subjects with moderate to severe sleep disorders. Randomized placebo-controlled trial, in a Population-based setting. Participants were adult patients 25 to 65 years old with a chronic primary insomnia who volunteered for the study. The tested intervention consisted of two soft gelatine capsules per day, containing either the dietary supplement (active group) or olive oil (placebo group) for a month. Subjects could also volunteer for two ancillary studies on melatonin and actigraphy. Evaluation criteria included i) perception of the quality of sleep at the end of treatment using the LSEQ questionnaire, ii) sleep efficiency measured by one-week actigraphic movement measurement performed before and during the treatment in a subsample of subjects, iii) night melatonin and 6 sulfatoxymelatonin (aMT6S) urine rates in a subsample of subjects. The average of Leeds score was similar in both groups (p = 0.95). A marked improvement in the quality of sleep was observed in both placebo (62%) and active (65%) group (p = 0.52). The evolution of urinary melatonin, aMT6S, and of the Mel/aMT6S ratio showed no differences between the two groups. Sleep efficiency, as measured by actigraphy, improved similarly in both groups during the treatment period, from 72% to 76% and 75% in the active and placebo group respectively (p = 0.91). The dietary supplement had neither effect on the perceived quality of sleep, nor on the melatonin metabolism and sleep-wake cycle. Trial registration: clinical trials.gov:NCT00484497


  • LONG-TERM ALTERATION OF DAILY MELATONIN, 6-SULFATOXYMELATONIN, CORTISOL, AND TEMPERATURE PROFILES IN BURN PATIENTS: A PRELIMINARY REPORT

    by Géraldine Pina, Jocelyne Brun, Sylvie Tissot, Bruno Claustrat

    Melatonin, which shows a robust nycthemeral rhythm, plays the role of an endogenous synchronizer, able to stabilize and reinforce circadian rhythms and maintain their mutual phase relationships. Additionally, melatonin is a potent antioxidant and displays immunological properties. Because free radical generation, immune dysfunction, and sleep and metabolic disorders are involved in the short- and long-term pathophysiology of the burn syndrome, we undertook the study of daily urine melatonin, 6-sulfatoxymelatonin (aMT6s, the main hepatic melatonin metabolite), and cortisol variations plus temperature profiles in burn patients using a non-invasive protocol. Eight patients (6 males, 2 females) were studied on three occasions after admission to the intensive care unit (early session: days 1 to 3; intermediate session: day 10; late session: days 20 to 30). Melatonin, aMT6s, and free cortisol levels were determined in urine samples collected at 4 h intervals over a continuous 24 h span. Core temperature was recorded daily. Controls consisted of healthy subjects in the same age range. Cosinor analysis of the data provided an evaluation of mesor, amplitude, and acrophase of circadian rhythms. Also, we calculated day (D), night (N), and 24 h hormone excretions, N/D ratio for melatonin and aMT6s, and D/N ratio for cortisol. These data were analyzed using Kruskal-Wallis test followed by multiple comparisons. Cosinor analysis did not detect a circadian rhythm in melatonin, aMT6s, or cortisol in any of the three sessions. D melatonin excretion displayed a major increase, resulting in a decreased N/D melatonin ratio, and the melatonin mesor (24 h mean) was increased in the early session, compared with controls. For aMT6s, only the early N/D ratio was decreased, and the mesor of the intermediate session increased. These results were not the consequence of hepatic and/or kidney alteration, as the patients' hepatic and renal parameters were in the normal range. The D and N melatonin/aMT6s ratios of controls and patients were similar, and the aMT6s profiles were superimposed on the melatonin ones, mainly during the day. The D, N, and 24 h cortisol values were increased in all sessions, except for the D level of the early session. The consistently increased mesors in the three sessions provided confirmation. The core temperature profiles were abnormal in all three sessions, mainly during the night, although there was a tendency toward normalization with time. The individual mesors were consistently increased compared with controls. Globally, the abnormalities we report could participate in the pathophysiology of short- and long-term alterations observed in burn syndrome, especially disturbances of sleep, metabolism, and immune function. (Author correspondence: bruno. claustrat@chu-lyon. fr ).


    • 1 January 2010
      • Vol. 31  (3) , 330-5

    Suppression of melatonin secretion in healthy subjects with eyeglass LED delivery system.

    by Bruno Claustrat, Jocelyne Brun, Françoise Borson-Chazot, Denis Cohen-Tannoudji, Francine Claustrat, Jacqueline Julien, Patrick Lemoine

    Practicability remains a problem in light therapy of biological rhythm disorders. We report here the effect on melatonin secretion of a device consisting of a prototype of eyeglasses including light emitting diodes (LED) in lenses (Somnavue). Light (1,200 lx) was administered in a randomised crossover design to ten healthy subjects with Somnavue for 1 or 2 hours, Lumino (a helmet which administers light) for 1 hour, and placebo, beginning at 01:00 h. Plasma melatonin concentrations were evaluated between 20:00-05:00 h. Multiple comparisons showed differences between placebo and Somnavue administered for one or two hours (p<0.01 and p<0.05 respectively) and Lumino and placebo (p<0.05). In conclusion, Somnavue was able to suppress melatonin. The development of such a device could increase adherence with light treatment in SAD or circadian rhythm sleep disorders.


  • Effect of Constant Light on Prolactin and Corticosterone Rhythms Evaluated Using a Noninvasive Urine Sampling Protocol in the Rat

    by B. Claustrat, J.-L. Valatx, C. Harthé, J. Brun

    Circadian prolactin and corticosterone rhythms are usually investigated in the rat by analysis of plasma hormone profiles. In order to develop a nonstressful methodology for long-term studies, we validated prolactin and corticosterone radioimmunoassays in rat urine samples. Among the criteria of validation, prolactin was identified in urine by Western blot whereas both prolactin and corticosterone levels were undetectable in the urine of hypophysectomized rats. The determination of prolactin and corticosterone levels on serial urine samples showed daily variations in male rats entrained by the light-dark cycle. The acrophases of the 24-hour prolactin and corticosterone profiles were located at 03:26 h and 23:32 h respectively, a delay of 3-4 hours compared with the values of the 24-hour plasma profiles reported in the literature. Corticosterone and prolactin rhythms were abolished or dramatically delayed after 3 weeks of constant illumination. As expected, constant light suppressed the rhythm of 6-sulfatoxymelatonin, the major hepatic metabolite of melatonin. The noninvasive and nonstressful methodology we developed could be of interest for studying the regulation of hormone rhythms and their mutual endocrine interactions in physiological conditions, especially their evolution in the aging process.


  • Top Cited Papers

    The basic physiology and pathophysiology of melatonin

    by Bruno Claustrat, Jocelyne Brun, Guy Chazot


  • Melatonin Secretion is Supersensitive to Light in Migraine

    by B Claustrat, J Brun, C Chiquet, G Chazot, F Borson-Chazot

    The present study examined the sensitivity to light of melatonin (MLT) secretion in familial migraine during a headache-free interval. Twelve female patients and 12 healthy controls were included in the trial. All subjects were studied twice. In each session, light exposure (300 lx) or placebo was randomly administered for 30 min between 00.30 and 01.00 h. Blood was sampled hourly between 20.00 and 24.00 h, and 02.00 and 04.00 h and every 15 min between 00.30 and 01.30 h. Plasma MLT levels were determined by radioimmunoassay. MLT suppression was more marked in the migraine group than in the control group [difference of area under curve (δAUC) = −53.8 ± 16.2 vs. 18.5 ± 12.7 pg/h/ml, P < 0.005; maximum of MLT suppression (δ) = −35.7 ± 10.2 vs.- 6.7 ± 5.8 pg/ml, P < 0.05]. These findings show a clear hypersensitivity to light in young female migraineurs during the headache-free period.